{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:59:08Z","timestamp":1792432748812,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":66,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.crphar.2021.100020","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T18:49:20Z","timestamp":1617043760000},"page":"100020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Drug-drug interactions in polypharmacy patients: The impact of renal impairment"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3916-7003","authenticated-orcid":false,"given":"Bianca","family":"Papotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Adorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pot\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crphar.2021.100020_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11604\/pamj.2017.28.199.13622","article-title":"Evaluation of drug-drug interactions among patients with chronic kidney disease in a South-Eastern Nigeria tertiary hospital: a retrospective study","volume":"28","author":"Adibe","year":"2017","journal-title":"Pan Afr. Med. J."},{"key":"10.1016\/j.crphar.2021.100020_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/8755122518788809","article-title":"Drug interactions with oral Inhaled medications","volume":"34","author":"Ajimura","year":"2018","journal-title":"J.\u00a0Pharm. Technol."},{"key":"10.1016\/j.crphar.2021.100020_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11096-019-00816-4","article-title":"Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review","volume":"41","author":"Al Raiisi","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.crphar.2021.100020_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-016-0317-4","article-title":"Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients","volume":"17","author":"Al-Ramahi","year":"2016","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/ndt\/gfh771","article-title":"Patterns of medication use in the RRI-CKD study: focus on medications with cardiovasculars effects","volume":"20","author":"Bailie","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.crphar.2021.100020_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe?","volume":"76","author":"Baker","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.crphar.2021.100020_bib7","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1001\/archinte.159.21.2553","article-title":"Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group","volume":"159","author":"Bates","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.crphar.2021.100020_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.crphar.2021.100020_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1586\/17512433.1.1.105","article-title":"Drug-drug interaction with statins","volume":"1","author":"Corsini","year":"2008","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.crphar.2021.100020_bib10","first-page":"28 4","article-title":"Prevalence of drug interactions in hospitalised elderly patients: a systematic review","author":"De Oliveira","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.crphar.2021.100020_bib11","first-page":"125","article-title":"Assessment of prescribed medications and pattern of distribution for potential drug-drug interactions among chronic kidney disease patients attending the nephrology clinic of lagos university teaching hospital in sub-saharan West Africa","volume":"9","author":"Fasipe","year":"2017","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"10.1016\/j.crphar.2021.100020_bib12","first-page":"88","article-title":"Prevalence and pattern of potential drug-drug interactions among chronic kidney disease patients in south-Western Nigeria","author":"Fasipe","year":"2017","journal-title":"Niger. Postgrad. Med. J."},{"key":"10.1016\/j.crphar.2021.100020_bib13","article-title":"How do we prevent the burden of extremely harmful and clinically nonbeneficial drug\u2013drug interactions among chronic kidney disease patients?","volume":"2","author":"Fasipe","year":"2018","journal-title":"Toxicol. Res. Appl."},{"key":"10.1016\/j.crphar.2021.100020_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pds.966","article-title":"Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database","volume":"14","author":"Fincke","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.crphar.2021.100020_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00508-009-1251-2","article-title":"Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments","volume":"122","author":"Fokter","year":"2010","journal-title":"Wien Klin. Wochenschr."},{"key":"10.1016\/j.crphar.2021.100020_bib16","first-page":"989","article-title":"Polypharmacy cutoff and outcomes\u00a0\u200b: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes","volume":"65","author":"Gnjidic","year":"2012"},{"key":"10.1016\/j.crphar.2021.100020_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11906-012-0250-2","article-title":"Lipid nephrotoxicity: new concept for an old disease","volume":"14","author":"Gyebi","year":"2012","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.crphar.2021.100020_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.japh.2019.05.010","article-title":"The missing piece: clinical pharmacists enhancing the interprofessional nephrology clinic model","volume":"59","author":"Hawley","year":"2019","journal-title":"J.\u00a0Am. Pharmaceut. Assoc."},{"key":"10.1016\/j.crphar.2021.100020_bib19","author":"Hegde"},{"key":"10.1016\/j.crphar.2021.100020_bib20","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis","volume":"7","author":"Hill","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.crphar.2021.100020_bib21","first-page":"1315","article-title":"Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation","volume":"12","author":"Hostetter","year":"2001","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib22","first-page":"2221","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.crphar.2021.100020_bib23","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am. J. kidney Dis. Off. J. Natl. Kidney Found."},{"key":"10.1016\/j.crphar.2021.100020_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/QAI.0b013e318160a542","article-title":"Drug\/drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers","volume":"47","author":"Kiser","year":"2008","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.crphar.2021.100020_bib25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2016.11.023","article-title":"Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency","volume":"152","author":"Lam","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crphar.2021.100020_bib26","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/bcp.13738","article-title":"Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort","volume":"84","author":"Laville","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.crphar.2021.100020_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.crphar.2021.100020_bib28","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.crphar.2021.100020_bib30","first-page":"259","article-title":"Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management","volume":"9","author":"Li","year":"2013","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.crphar.2021.100020_bib31","first-page":"75 179","article-title":"Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units","author":"Maison","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.crphar.2021.100020_bib32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/106002809502900610","article-title":"Interactions between antipsychotic and antihypertensive drugs","volume":"29","author":"Markowitz","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.crphar.2021.100020_bib33","first-page":"26","article-title":"Identifying potential drug interactions in chronic kidney disease patients","volume":"36","author":"Marquito","year":"2014","journal-title":"J.\u00a0Bras. Nefrol. \u02b9org\u00e3o Of. Soc. Bras. e Latino-Americana Nefrol."},{"key":"10.1016\/j.crphar.2021.100020_bib34","series-title":"What Is Polypharmacy\u00a0\u200b? A Systematic Review of Definitions","first-page":"1","author":"Masnoon","year":"2017"},{"key":"10.1016\/j.crphar.2021.100020_bib35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ki.2011.322","article-title":"Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease: improving Global Outcomes (KDIGO)","volume":"80","author":"Matzke","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.crphar.2021.100020_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/joim.12846","article-title":"Iron deficiency anaemia due to proton pump inhibitors: clinical impact revealed","volume":"285","author":"McCarthy","year":"2019","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.crphar.2021.100020_bib37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.bjp.0706138","article-title":"Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450","volume":"144","author":"Michaud","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.crphar.2021.100020_bib38","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1681\/ASN.2006010035","article-title":"Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure","volume":"17","author":"Michaud","year":"2006","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1254\/jphs.08042FP","article-title":"Effect of hemodialysis on hepatic cytochrome P450 functional expression","volume":"108","author":"Michaud","year":"2008","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.crphar.2021.100020_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.crphar.2021.100020_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/CLEP.S153458","article-title":"The epidemiology of polypharmacy in older adults: register-based prospective cohort study","volume":"10","author":"Morin","year":"2018","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.crphar.2021.100020_bib42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/clpt.2008.59","article-title":"Emerging evidence of the impact of kidney disease on drug metabolism and transport","volume":"83","author":"Nolin","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.crphar.2021.100020_bib43","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1681\/ASN.2009010082","article-title":"ESRD Impairs nonrenal clearance of fexofenadine but not midazolam","volume":"20","author":"Nolin","year":"2009","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.21804\/22-1-3577","article-title":"Evaluation of potential drug\u2013drug interactions among patients with chronic kidney disease in northeastern Nigeria","volume":"22","author":"Okoro","year":"2019","journal-title":"African J. Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000321857","article-title":"A\u00a0quantitative approach to drug dosing in chronic kidney disease","volume":"31","author":"Olyaei","year":"2011","journal-title":"Blood Purif."},{"key":"10.1016\/j.crphar.2021.100020_bib46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1542-4758.2009.00328.x","article-title":"Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a 2-year randomized, controlled study","volume":"13","author":"Pai","year":"2009","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.crphar.2021.100020_bib47","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1592\/phco.29.12.1433","article-title":"Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study","volume":"29","author":"Pai","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.crphar.2021.100020_bib48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/ckj\/sfz072","article-title":"J.\u00a0Is polypharmacy an increasing burden in chronic kidney disease? the German experience","volume":"12","author":"Parker","year":"2019","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.crphar.2021.100020_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrneph.2009.213","article-title":"Fluid balance and acute kidney injury","volume":"6","author":"Prowle","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0250-474X.102545","article-title":"Assessment of drug-drug interactions among renal failure patients of nephrology ward in a south Indian tertiary care hospital","volume":"74","author":"Rama","year":"2012","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"10.1016\/j.crphar.2021.100020_bib51","first-page":"71","article-title":"Clinical relevancy and determinants of potential drug \u2013 drug interactions in chronic kidney disease patients: results from a retrospective analysis","author":"Saleem","year":"2017","journal-title":"Integrated Pharm. Res. Pract."},{"key":"10.1016\/j.crphar.2021.100020_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ndt\/gfs436","article-title":"Exploring the role of pharmacists in outpatient dialysis centers: a qualitative study of nephrologist views","volume":"28","author":"Salgado","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.crphar.2021.100020_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12080713","article-title":"Prevalence of potential drug\u2013drug interaction risk among chronic kidney disease patients in a Spanish hospital","volume":"12","author":"Santos-D\u00edaz","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.crphar.2021.100020_bib54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/0250-474X.33149","article-title":"Medication knowledge of hemodialysis patients and influence of clinical pharmacist provided education on their knowledge","volume":"69","author":"Sathvik","year":"2007","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"10.1016\/j.crphar.2021.100020_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/ckj\/sfz046","article-title":"Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study","volume":"12","author":"Schmidt","year":"2019","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.crphar.2021.100020_bib56","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40266-018-0563-1","article-title":"Kidney function, polypharmacy, and potentially inappropriate medication use in a community-based cohort of older adults","volume":"35","author":"Secora","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.crphar.2021.100020_bib57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.15448\/1980-6108.2014.4.17637","article-title":"Assessment of used medications and drug-drug interactions among chronic renal failure patients","volume":"24","author":"Sgnaolin","year":"2014","journal-title":"Sci. Med."},{"key":"10.1016\/j.crphar.2021.100020_bib58","first-page":"63","article-title":"Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers","volume":"24","author":"Shahzadi","year":"2011","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.crphar.2021.100020_bib59","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1021\/acs.jmedchem.5b00201","article-title":"Volume of distribution in drug design","volume":"58","author":"Smith","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.crphar.2021.100020_bib60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40266-020-00747-0","article-title":"Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy","volume":"37","author":"Sommer","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.crphar.2021.100020_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2369-12-35","article-title":"Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review","volume":"12","author":"Stemer","year":"2011","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.crphar.2021.100020_bib62","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.crphar.2021.100020_bib68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/picr.PICR_110_18","article-title":"Evaluation of prescribing practices and drug-related problems in chronic kidney disease patients: A cross-sectional study","volume":"11","author":"Subeesh","year":"2020","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.crphar.2021.100020_bib63","article-title":"Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure","volume":"9","author":"Testani","year":"2016","journal-title":"Circ. Hear. Fail."},{"key":"10.1016\/j.crphar.2021.100020_bib64","first-page":"18 157","article-title":"Management of statin Intolerance in 2018: still more questions than answers","author":"Toth","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.crphar.2021.100020_bib65","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ki.2013.399","article-title":"Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport","volume":"85","author":"Yeung","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.crphar.2021.100020_bib66","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1248\/bpb.25.1077","article-title":"Effect of experimental renal failure on the pharmacokinetics of losartan in rats","volume":"25","author":"Yoshitani","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.crphar.2021.100020_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/clpt.2008.208","article-title":"Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications","volume":"85","author":"Zhang","year":"2009","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257121000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257121000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:52:01Z","timestamp":1762923121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257121000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":68,"alternative-id":["S2590257121000079"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2021.100020","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions in polypharmacy patients: The impact of renal impairment","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2021.100020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100020"}}